{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:42:16Z","timestamp":1767829336881,"version":"3.49.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zenyaku Kogyo Co., Ltd.","award":["ANZ2170030"],"award-info":[{"award-number":["ANZ2170030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1470-3","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T13:05:59Z","timestamp":1564751159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial)"],"prefix":"10.1186","volume":"20","author":[{"given":"China","family":"Nagano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Sako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ishikura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Omori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-8174","authenticated-orcid":false,"given":"Kazumoto","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"issue":"12","key":"1470_CR1","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s004670100021","volume":"16","author":"PA Mc Kinney","year":"2001","unstructured":"Mc Kinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatric nephrology. 2001;16(12):1040\u20134.","journal-title":"Pediatric nephrology"},{"issue":"4","key":"1470_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10157-016-1319-z","volume":"21","author":"Kaori Kikunaga","year":"2016","unstructured":"et al. Kikunaga K, Ishikura K, Terano C, Sato M, Komaki F, Hamasaki Y, High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan (JP-SHINE study). Clin Exp Nephrol. 2017;21(4):651\u20137.","journal-title":"Clinical and Experimental Nephrology"},{"key":"1470_CR3","doi-asserted-by":"crossref","unstructured":"Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. The Cochrane Database Syst Rev. 2015;(3):CD001533.","DOI":"10.1002\/14651858.CD001533.pub5"},{"issue":"10","key":"1470_CR4","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2215\/CJN.05691108","volume":"4","author":"HA Kyrieleis","year":"2009","unstructured":"Kyrieleis HA, L\u00f6wik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol. 2009;4(10):1593\u2013600.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9950","key":"1470_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384(9950):1273\u201381.","journal-title":"Lancet"},{"key":"1470_CR6","doi-asserted-by":"crossref","unstructured":"Ravani P, Bonanni A, Rossi R, Caridi G, Ghiggeri GMAnti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children. Clin J Am Soc Nephrol. 2016;11(4):710\u201320.","DOI":"10.2215\/CJN.08500815"},{"issue":"6","key":"1470_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6(6):1308\u201315.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"1470_CR8","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","volume":"32","author":"K Kamei","year":"2017","unstructured":"Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, et al. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatric nephrology. 2017;32(11):2071\u20138.","journal-title":"Pediatric nephrology"},{"key":"1470_CR9","unstructured":"Vivarelli M, Desch\u00eanes G Idiopathic Nephrotic syndrome Working Group Report, September 2016. \n                    http:\/\/espn-online.org\/images\/IdiopathicNephroticsyndromeWorkingGroupReport2016.pdf\n                    \n                  . Accessed 3 Apr 2017."},{"issue":"9","key":"1470_CR10","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, et al. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol. 2015;26(9):2259\u201366.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1470_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, TKS M, et al. Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial. JAMA Pediatr. 2018;172(8):757\u201364.","journal-title":"JAMA Pediatr"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1470-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T08:44:25Z","timestamp":1596271465000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1470-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1470-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"17 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is being performed in accordance with the Declaration of Helsinki. The study protocol is currently being reviewed by Tokyo Metropolitan Children\u2019s Hospital Institutional Review Board (IRB), but has already been approved by the IRB of each of 11 other hospitals. The IRB names and a reference number are as follows:","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mayumi Sako received a consulting fee from Zenyaku Kogyo Co. Ltd. Kenji Ishikura received a grant from Chugai Pharmaceutical Co., Ltd. and Novartis Pharma K.K., and a lecture fee from Zenyaku Kogyo Co. Ltd. and Novartis Pharma K.K. Koichi Kamei has received lecture fees from Chugai Pharmaceutical Co., Ltd. Koichi Nakanishi received lecture fees from Chugai Pharmaceutical Co., Ltd. and Novartis Pharma K.K. Kandai Nozu received lecture fees from Chugai Pharmaceutical Co., Ltd. Kazumoto Iijima received a grant from Zenyaku Kogyo Co. Ltd. and lecture and\/or consulting fees from Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co. Ltd., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K. and Kyowa Hakko Kirin Co. Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"293"}}